Clinical Trial Update: Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria [Phase 4]

View source ↗

Summary

Phase 4 clinical trial updating on extending omalizumab treatment intervals for chronic spontaneous urticaria; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Chronic Urticaria
• Spontaneous Urticaria
• Urticaria

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Simon Francis Thomsen | Conditions: Chronic Spontaneous Urticaria, Chronic Urticaria, Idiopathic | Phase 4 | Status: RECRUITING